Ken Griffin Zentalis Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 7,900 shares of ZNTL stock, worth $9,401. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,900

Previous 7,400 6.76%

Holding current value

$9,401

Previous $22,000 45.45%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$1.59 - $3.24 $5 Million - $10.2 Million	-3,145,669 Reduced 97.79%	71,058 $112,000
Q4 2024 Feb 14, 2025	BUY	$2.7 - $4.03 $1.35 Million - $2.01 Million	499,206 Added 18.37%	3,216,727 $9.75 Million
Q3 2024 Nov 14, 2024	SELL	$2.9 - $4.57 $5.18 Million - $8.16 Million	-1,785,392 Reduced 39.65%	2,717,521 $9.97 Million
Q2 2024 Aug 14, 2024	BUY	$4.09 - $16.13 $2.66 Million - $10.5 Million	650,484 Added 16.89%	4,502,913 $18.4 Million
Q1 2024 May 15, 2024	BUY	$10.83 - $16.49 $1.85 Million - $2.81 Million	170,647 Added 4.63%	3,852,429 $60.7 Million
Q4 2023 Feb 14, 2024	BUY	$9.84 - $20.13 $15 Million - $30.7 Million	1,526,431 Added 70.82%	3,681,782 $55.8 Million
Q3 2023 Nov 14, 2023	BUY	$19.63 - $28.29 $511,459 - $737,095	26,055 Added 1.22%	2,155,351 $43.2 Million
Q2 2023 Aug 14, 2023	BUY	$17.41 - $30.05 $13.9 Million - $24 Million	799,303 Added 60.1%	2,129,296 $60.1 Million
Q1 2023 May 15, 2023	BUY	$16.14 - $24.94 $11.2 Million - $17.3 Million	692,273 Added 108.55%	1,329,993 $22.9 Million
Q4 2022 Feb 14, 2023	BUY	$18.07 - $25.6 $1.53 Million - $2.17 Million	84,919 Added 15.36%	637,720 $12.8 Million
Q3 2022 Nov 14, 2022	SELL	$20.23 - $31.73 $4.25 Million - $6.66 Million	-209,894 Reduced 27.52%	552,801 $12 Million
Q2 2022 Aug 15, 2022	BUY	$17.91 - $52.25 $4.51 Million - $13.1 Million	251,670 Added 49.25%	762,695 $21.4 Million
Q1 2022 May 16, 2022	SELL	$41.58 - $80.89 $3.68 Million - $7.17 Million	-88,611 Reduced 14.78%	511,025 $23.6 Million
Q4 2021 Feb 14, 2022	SELL	$66.92 - $84.79 $33.7 Million - $42.7 Million	-503,157 Reduced 45.63%	599,636 $50.4 Million
Q3 2021 Nov 15, 2021	SELL	$46.83 - $73.5 $6.1 Million - $9.57 Million	-130,187 Reduced 10.56%	1,102,793 $73.5 Million
Q2 2021 Aug 16, 2021	BUY	$37.41 - $62.25 $6.64 Million - $11.1 Million	177,591 Added 16.83%	1,232,980 $65.6 Million
Q1 2021 May 17, 2021	SELL	$35.69 - $52.72 $16 Million - $23.6 Million	-448,481 Reduced 29.82%	1,055,389 $45.8 Million
Q4 2020 Feb 16, 2021	SELL	$31.71 - $57.97 $5.89 Million - $10.8 Million	-185,764 Reduced 10.99%	1,503,870 $78.1 Million
Q3 2020 Nov 16, 2020	BUY	$27.03 - $47.97 $3.49 Million - $6.19 Million	128,947 Added 8.26%	1,689,634 $55.2 Million
Q2 2020 Aug 14, 2020	BUY	$23.2 - $54.8 $36.2 Million - $85.5 Million	1,560,687 New	1,560,687 $74.9 Million

Others Institutions Holding ZNTL

# of Institutions

140

Shares Held

60.7M

Call Options Held

7.9K

Put Options Held

42.5K

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $67.8M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account